Top Markets
#1 Akedo Akedo +85.57%
#2 TENDIES TENDIES +76.85%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +42.83%
#5 Mubarak Mubarak +30.39%
#6 MultiversX MultiversX +28.68%
#7 Bitway Bitway +24.57%
#8 Cash Cat Cash Cat +23.24%
#9 Palladium Network Palladium Network +22.68%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rang in aandelen #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aandeelprijs
$8.16
Laatst gesynchroniseerd: 2025-06-26
Marktkapitalisatie
$234.57M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)

Categorie

Healthcare
Winst voor Regulus Therapeutics Inc. (RGLS)
Winst in Mar 2025 TTM: $-47.52M
Volgens de meest recente financiële verslagen van Regulus Therapeutics Inc. bedraagt de huidige winst van het bedrijf $-47.52M. In 2023 behaalde het bedrijf een winst van $-30.04M, een daling ten opzichte van de winst van 2022, die $-28.32M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Regulus Therapeutics Inc. van 2010 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-47.52M 2.51%
2024 $-46.36M 54.34%
2023 $-30.04M 6.05%
2022 $-28.32M 1.85%
2021 $-27.81M 76.78%
2020 $-15.73M -15.39%
2019 $-18.59M -61.78%
2018 $-48.65M -32.53%
2017 $-72.10M -11.90%
2016 $-81.84M 46.76%
2015 $-55.77M -1.61%
2014 $-56.68M 203.24%
2013 $-18.69M 7.31%
2012 $-17.42M 135.51%
2011 $-7.40M -52.56%
2010 $-15.59M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -11,199.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -4,204.73%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 6,395.94%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 8,351.24%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH